Sulfasalazine, an anti-inflammatory treatment approved by the FDA, appears to suppress xCT-mediated uptake of cystine [44] and attenuate growth of xenografted tumors derived from breast cancer cells [41], non-small cell lung cancer (NSCLC) cells [45], and lymphoma cells [46] (Figure 1A and Table 2). Here, SLC7A11 is linked to non-small cell lung carcinoma.